Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C8H14N2O2 |
Molecular Weight | 170.209 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC[C@H](N1CCCC1=O)C(N)=O
InChI
InChIKey=HPHUVLMMVZITSG-LURJTMIESA-N
InChI=1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1
Molecular Formula | C8H14N2O2 |
Molecular Weight | 170.209 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:36:39 UTC 2023
by
admin
on
Fri Dec 15 15:36:39 UTC 2023
|
Record UNII |
44YRR34555
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175753
Created by
admin on Fri Dec 15 15:36:39 UTC 2023 , Edited by admin on Fri Dec 15 15:36:39 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
LEVETIRACETAM ACTAVIS GROUP (AUTHORIZED: EPILEPSY)
Created by
admin on Fri Dec 15 15:36:39 UTC 2023 , Edited by admin on Fri Dec 15 15:36:39 UTC 2023
|
||
|
WHO-VATC |
QN03AX14
Created by
admin on Fri Dec 15 15:36:39 UTC 2023 , Edited by admin on Fri Dec 15 15:36:39 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
MATEVER (AUTHORIZED: EPILEPSY)
Created by
admin on Fri Dec 15 15:36:39 UTC 2023 , Edited by admin on Fri Dec 15 15:36:39 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
KEPRA (AUTHORIZED: EPILEPSY)
Created by
admin on Fri Dec 15 15:36:39 UTC 2023 , Edited by admin on Fri Dec 15 15:36:39 UTC 2023
|
||
|
LIVERTOX |
NBK548785
Created by
admin on Fri Dec 15 15:36:39 UTC 2023 , Edited by admin on Fri Dec 15 15:36:39 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
LEVETIRACETAM ACCORD (AUTHORIZED: EPILEPSY)
Created by
admin on Fri Dec 15 15:36:39 UTC 2023 , Edited by admin on Fri Dec 15 15:36:39 UTC 2023
|
||
|
NCI_THESAURUS |
C264
Created by
admin on Fri Dec 15 15:36:39 UTC 2023 , Edited by admin on Fri Dec 15 15:36:39 UTC 2023
|
||
|
NDF-RT |
N0000008486
Created by
admin on Fri Dec 15 15:36:39 UTC 2023 , Edited by admin on Fri Dec 15 15:36:39 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
LEVETIRACETAM HOSPIRA (AUTHORIZED: EPILEPSY)
Created by
admin on Fri Dec 15 15:36:39 UTC 2023 , Edited by admin on Fri Dec 15 15:36:39 UTC 2023
|
||
|
WHO-ATC |
N03AX14
Created by
admin on Fri Dec 15 15:36:39 UTC 2023 , Edited by admin on Fri Dec 15 15:36:39 UTC 2023
|
||
|
FDA ORPHAN DRUG |
303310
Created by
admin on Fri Dec 15 15:36:39 UTC 2023 , Edited by admin on Fri Dec 15 15:36:39 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
LEVETIRACETAM RATIOPHARM (AUTHORIZED: EPILEPSY)
Created by
admin on Fri Dec 15 15:36:39 UTC 2023 , Edited by admin on Fri Dec 15 15:36:39 UTC 2023
|
||
|
NCI_THESAURUS |
C1509
Created by
admin on Fri Dec 15 15:36:39 UTC 2023 , Edited by admin on Fri Dec 15 15:36:39 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
LEVETIRACETAM SUN (AUTHORIZED: EPILEPSY)
Created by
admin on Fri Dec 15 15:36:39 UTC 2023 , Edited by admin on Fri Dec 15 15:36:39 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
LEVETIRACETAM ACTAVIS (AUTHORIZED: EPILEPSY)
Created by
admin on Fri Dec 15 15:36:39 UTC 2023 , Edited by admin on Fri Dec 15 15:36:39 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
LEVETIRACETAM TEVA (AUTHORIZED: EPILEPSY)
Created by
admin on Fri Dec 15 15:36:39 UTC 2023 , Edited by admin on Fri Dec 15 15:36:39 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB01202
Created by
admin on Fri Dec 15 15:36:39 UTC 2023 , Edited by admin on Fri Dec 15 15:36:39 UTC 2023
|
PRIMARY | |||
|
CHEMBL1286
Created by
admin on Fri Dec 15 15:36:39 UTC 2023 , Edited by admin on Fri Dec 15 15:36:39 UTC 2023
|
PRIMARY | |||
|
m6783
Created by
admin on Fri Dec 15 15:36:39 UTC 2023 , Edited by admin on Fri Dec 15 15:36:39 UTC 2023
|
PRIMARY | Merck Index | ||
|
7528
Created by
admin on Fri Dec 15 15:36:39 UTC 2023 , Edited by admin on Fri Dec 15 15:36:39 UTC 2023
|
PRIMARY | |||
|
100000091669
Created by
admin on Fri Dec 15 15:36:39 UTC 2023 , Edited by admin on Fri Dec 15 15:36:39 UTC 2023
|
PRIMARY | |||
|
44YRR34555
Created by
admin on Fri Dec 15 15:36:39 UTC 2023 , Edited by admin on Fri Dec 15 15:36:39 UTC 2023
|
PRIMARY | |||
|
6450
Created by
admin on Fri Dec 15 15:36:39 UTC 2023 , Edited by admin on Fri Dec 15 15:36:39 UTC 2023
|
PRIMARY | |||
|
760119
Created by
admin on Fri Dec 15 15:36:39 UTC 2023 , Edited by admin on Fri Dec 15 15:36:39 UTC 2023
|
PRIMARY | |||
|
102767-28-2
Created by
admin on Fri Dec 15 15:36:39 UTC 2023 , Edited by admin on Fri Dec 15 15:36:39 UTC 2023
|
PRIMARY | |||
|
1563
Created by
admin on Fri Dec 15 15:36:39 UTC 2023 , Edited by admin on Fri Dec 15 15:36:39 UTC 2023
|
PRIMARY | |||
|
6437
Created by
admin on Fri Dec 15 15:36:39 UTC 2023 , Edited by admin on Fri Dec 15 15:36:39 UTC 2023
|
PRIMARY | |||
|
LEVETIRACETAM
Created by
admin on Fri Dec 15 15:36:39 UTC 2023 , Edited by admin on Fri Dec 15 15:36:39 UTC 2023
|
PRIMARY | |||
|
DTXSID9023207
Created by
admin on Fri Dec 15 15:36:39 UTC 2023 , Edited by admin on Fri Dec 15 15:36:39 UTC 2023
|
PRIMARY | |||
|
6826
Created by
admin on Fri Dec 15 15:36:39 UTC 2023 , Edited by admin on Fri Dec 15 15:36:39 UTC 2023
|
PRIMARY | |||
|
Levetiracetam
Created by
admin on Fri Dec 15 15:36:39 UTC 2023 , Edited by admin on Fri Dec 15 15:36:39 UTC 2023
|
PRIMARY | |||
|
1359404
Created by
admin on Fri Dec 15 15:36:39 UTC 2023 , Edited by admin on Fri Dec 15 15:36:39 UTC 2023
|
PRIMARY | |||
|
5284583
Created by
admin on Fri Dec 15 15:36:39 UTC 2023 , Edited by admin on Fri Dec 15 15:36:39 UTC 2023
|
PRIMARY | |||
|
LL-100
Created by
admin on Fri Dec 15 15:36:39 UTC 2023 , Edited by admin on Fri Dec 15 15:36:39 UTC 2023
|
PRIMARY | |||
|
44YRR34555
Created by
admin on Fri Dec 15 15:36:39 UTC 2023 , Edited by admin on Fri Dec 15 15:36:39 UTC 2023
|
PRIMARY | |||
|
114477
Created by
admin on Fri Dec 15 15:36:39 UTC 2023 , Edited by admin on Fri Dec 15 15:36:39 UTC 2023
|
PRIMARY | RxNorm | ||
|
SUB08459MIG
Created by
admin on Fri Dec 15 15:36:39 UTC 2023 , Edited by admin on Fri Dec 15 15:36:39 UTC 2023
|
PRIMARY | |||
|
C47581
Created by
admin on Fri Dec 15 15:36:39 UTC 2023 , Edited by admin on Fri Dec 15 15:36:39 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
EP
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
TARGET->LIGAND |
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
||
|
RACEMATE -> ENANTIOMER |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 0.5
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Levetiracetam and brivaracetam inhibit SV2A’s role in trafficking vesicles to the releasable pool of vesicles
|